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Abstract
OBJECTIVE: To systematically evaluate the clinical
efficacy and safety of puerarin injection in the treat-
ment of diabetic peripheral neuropathy (DPN).
METHODS: Randomized controlled trials investi-
gating the efficacy of puerarin injection on DPN
were searched for in China National Knowledge In-
frastructure Database, Chinese Scientific Journals
Database, Wanfang Database, Chinese Biomedical
Literature Database, PubMed, and Cochrane Li-
brary from establishment to April 30. Two reviewers
independently retrieved and extracted the informa-
tion. The included studies were assessed by the Co-
chrane risk of bias and analyzed by Review Manag-
er 5.2 software.
RESULTS: Twenty-two studies involving 1664 par-
ticipants were included. The quality of the studies
was found to be relatively low. Meta-analysis
showed that puerarin injection combined with
western medication was more effective than con-
ventional therapy for DPN in terms of total effective
rate, nerve conduction velocity (NCV), and
hemorheology index. Six adverse drug reactions
(ADRs) from puerarin injection were reported in
two studies. Reactions included facial flushing, pal-
pitations, and pain at infusion locations. However,
no serious ADRs were reported.
CONCLUSION: Puerarin injection was effective for
the treatment of DPN. Puerarin can improve the to-
tal effective rate, correct NCV that was decreased
by diabetes, and improve the hemorheology index.
Puerarin was also relatively safe clinically. However,
since the articles included in the study were not
high-quality, more studies should be conducted to
strengthen their findings.
© 2014 JTCM. All rights reserved.
Key words: Puerarin; Diabetic neuropathies; Treat-
ment outcome; Meta-analysis; Randomized con-
trolled trials
INTRODUCTION
Diabetic peripheral neuropathy (DPN) is one of the
most common neuropathies caused by diabetes melli-
tus (DM). Its prevalence is 30%-90%.1 DPN is one of
the most debilitating factors in DM patients.2 The clin-
ical symptoms of DPN are intermittent, persistent
limb pain, featuring burning or chisel-like sensations.
The symptoms are often aggravated at rest or at night.
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Patients may develop hypoesthesia or suffer paresthesia
with numbness or electric shock-like sensations.3 Some
studies showed that both the relationships between
prevalence and course and prevalence and severity of
DM were not obvious.4 If patients with DPN can be
diagnosed earlier, then given timely positive blood glu-
cose control and necessary foot care, they can avoid
foot ulcers, gangrene, amputation, and other serious
consequences.5
For Western Medicine, no effective therapy is available
for the treatment of DPN. Methylcobalamin and neu-
rotrophin are usually used clinically, but they are ex-
pensive and have a long course of treatment.2 Tradi-
tional Chinese Medicine (TCM) provides an option
for DPN treatment and has shown certain advantages
over Western Medicine. TCM physicians consider the
pathology of DPN to be a stasis syndrome. The key of
the pathogenesis is Yang deficiency and collateral sta-
sis. After the 1990s, puerarin injection has been used
for the treatment of DPN. Puerarin is one of the flavo-
noids extracted from Gegen (Radix Puerariae Lobatae).6
Modern pharmacological studies7 have confirmed that
puerarin can lower blood sugar, significantly improve
microcirculation, expand the coronary arteries, reduce
platelet aggregation and blood viscosity, and improve
the sensitivity of insulin receptors.
Therefore, this systematic review aimed to evaluate the
efficacy and safety of puerarin injection for the treat-
ment of DPN to provide a scientific basis for its use.
METHODS
Database searched
Two reviewers searched the following databases from
establishment to April 30, 2013: China National
Knowledge Infrastructure, Wanfang Data, Chinese Sci-
entific Journals Database, Chinese Biomedical Litera-
ture Database, PubMed, and Cochrane Library. The
search terms were "Puerarin injection" and "diabetic
peripheral neuropathy." Studies published in English
or Chinese were considered.
Inclusion criteria
Studies that met the following criteria were included:
randomized controlled trials (RCTs) administering pu-
erarin for DPN, irrespective of publishing language,
and DPN caused by DM including both type Ⅰ and
type Ⅱ. Cases were excluded if the DPN was caused
by other diseases. Age, sex, and race were not limited.
The diagnostic criteria of DM were World Health Or-
ganization diagnostic criteria for diabetes (1999), or
American Diabetes Association diagnostic criteria
(1997). The diagnostic criteria of DPN followed the
"Diabetes TCM Prevention Guide: diabetic peripheral
neuropathy" released by Association of Chinese Medi-
cine in 2007.3 All participants blood glucose levels and
nerve conduction velocity (NCV) indexes were avail-
able.8
Intervention measures
Both the control and experimental groups received pri-
mary treatment to strictly control blood glucose, im-
prove microcirculation, correct metabolic disorders, di-
late blood vessels, and nourish nerves. In the control
group, the conventional medications for DPN were
methylcobalamin, PGE 1, vitamin B, and nimodipine.
The therapy for the experimental group was puerarin
injection combined with the medications of the con-
trol group. The main interventions were puerarin vs
Western Medicine, puerarin + Western Medicine vs
Western Medicine. The therapy for the experimental
group did not include any other TCM medications.
Outcomes
Primary outcome was the total effective rate. The total
effective rate=(the number of patients with significant
effect+the number of patients with effect)/ total num-
ber of patients. A "significant effect" meant that limb
pain, numbness, and fatigue were significantly re-
duced, nighttime sleep was improved, and NCV from
electromyography increased >5 m/s or returned to nor-
mal. An "effect" meant that the symptoms mentioned
above were relieved, and NCV compared with
pre-treatment increased <5 m/s. "Failure" meant that
the symptoms did not improve, and there were no
changes in NCV. Secondary outcomes included
hemorheology index with glycosylated hemoglobin
(HbA1c), fibrinogen (Fb), and plasma viscosity (ηp).
The NCV index of peroneal nerve and median nerve
included the motor nerve conduction velocity
(MNCV) and sensory nerve conduction velocity
(SNCV). The number of adverse drug reactions
(ADR)/adverse drug events (ADE) occurred was
counted.
Data extraction and quality assessment
For the included studies, data were extracted indepen-
dently by two reviewers according to the inclusion cri-
teria, intervention measures, and outcomes. Disagree-
ment was resolved through discussion or assistance by
a third researcher. Data included study type, patient
characteristics, and information about treatment. We
assessed the risk of bias of the included trials strictly ac-
cording to the Cochrane risk of bias tool, which includ-
ed random sequence generation, allocation conceal-
ment, blinding of participants and research staff, blind-
ing of outcome assessment, incomplete outcome data,
selective reporting, and other bias. For each item, there
were three choices: low risk of bias, unclear, and high
risk of bias. When inadequate information was present-
ed in the article and we were unable to explicitly judge
the item with "high, low or unclear."
Statistical analysis
The Revman 5.2 software9 package was used to analyze
data. Relative risk (RR) was used for dichotomous data
and mean difference (MD) was used for continuous
variables, both with 95% confidence interval (95%
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CI). Chi-squared test was used for checking heterogene-
ity between studies, and I2 shows the degree of hetero-
geneity. Groups were divided into subgroups based on
the different kinds of medicines in a clinical setting.
Sensitivity analysis was performed to inspect the stabili-
ty of the results.
RESULTS
Assessment of quality
We retrieved 120 articles from the databases with the
search terms. After excluding duplicates, reviews, and
obviously irrelevant studies by reading titles and ab-
stracts, 52 papers were downloaded for further assess-
ment. After reading the full texts, studies that did not
meet the inclusion criteria were excluded. In the end,
22 studies involving 1664 patients were included.10-31
All articles were indexed in the Chinese journal litera-
ture database from 2000 to 2011 (Figure 1). Of the
1664 participants, 919 patients were in the puerarin
group, while 745 were in the control group. The aver-
age age of the patients was 54. The youngest patient
was 8 years old, while the oldest was 88. The sex ratio
was almost equal. The diagnosis of all participants in-
cluded type Ⅰ and type Ⅱ DM. The course of DM
was from half a year to 34 years. The courses of DPN
were from one month to 17 years. All patients had
their blood glucose controlled by oral hypoglycemic
agents or insulin. After control of blood glucose, they
received treatment for DPN. Of the 22 studies,
nine23-31 used puerarin injection compared with Vita-
min (V) B, 654-2, or Danshen injection. In the re-
maining studies, the puerarin group used puerarin in-
jection plus the therapies of the control group (Table
1).
Study quality was evaluated by Cochrane risk of bias
tool. Only four studies12,28,29,31 described the methods
used to generate the allocation sequence, and one
study28 described its blinding method. No studies re-
ported incomplete results (Figures 2, 3)
Outcomes
Total effective rates: cause of the differences in clinical
medicine used, all of the studies were divided into sub-
groups. The results of each subgroup were analyzed as
follows:
Puerarin+ control+basic treatment vs control+basic
treatment
Puerarin + nimodipine vs nimodipine: there were two
studies in the first subgroup.10,11 The test for heterogene-
ity was not significant (P=1.00, I2=0% ). We used a
fixed mode to analyze the studies. Combining the data
and analysis, the results showed that the puerarin com-
bined with nimodipine therapy was more effective
than nimodipine used alone. The difference was signifi-
cant between the two groups [RR=1.63, 95% CI (1.32,
2.03), P<0.000 01, Figure 4].
Puerarin+VB vs VB: there were four studies in this sub-
group.12-15 The test for heterogeneity was not signifi-
cant (P=0.25, I2=27%). We used a fixed mode to ana-
lyze the studies. The results showed that puerarin com-
bined with VB therapy was more effective than VB used
alone. The difference between the two groups was sig-
nificant [RR=1.63, 95% CI (1.37, 1.95), P<0.000 01,
Figure 4].
Puerarin+VB+mecobalamin vs VB+ mecobalamin: there
CNKI
n=71
Duplicated n=41
Irrelevant, animal study,
reviews n=27
CBM
n=12
VIP
n=14
Wanfang
n=23
Pubmed
n=0
Cochrane
n=0
Total
n=120
Exclude
Full text
n=52
Exclude
Cases n=9
Not meet the inclusion
criteria n=21
RCT
Included
n=22
Figure 1 Flow chart of literature search
CNKI: China National Knowledge Infrastructure Database; VIP: Chinese Scientific Journals Database; CBM: Chinese Biomedical Lit-
erature Database; RCT: randomized controlled trials.
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were two studies21,22 in this subgroup. The test for het-
erogeneity was not significant (P=0.74, I2=0% ). We
used a fixed mode to analyze the studies. The results
showed that puerarin combined with mecobalamin
and VB therapy was more effective than mecobalamin
and VB combined. The difference between the two
groups was significant [RR=1.46, 95%CI (1.15, 1.84),
P=0.002, Figure 4].
Puerarin + mecobalamin vs mecobalamin: there were
five studies16-20 in this subgroup. The test for heteroge-
neity showed no differences between the studies and a
random mode was used for analysis. The results
showed that puerarin combined with mecobalamin
therapy was more effective than mecobalamin used
alone. The difference between the two groups was sig-
nificant [RR=1.24, 95%CI (1.09, 1.40), P=0.0009, Fig-
ure 5].
Puerarin+basic treatment vs control+ basic treatment
Puerarin vs VB: there were four studies23-26 in this sub-
group. The test for heterogeneity was not significant
(P=0.79, I2=0%). A fixed mode was used to analyze the
studies. The results showed that puerarin was more ef-
fective than VB. The difference between the two groups
was significant [RR=1.91, 95% CI (1.56, 2.34), P<
0.000 01, Figure 6].
Puerarin vs Danshen injection: there were three stud-
ies27-29 in this subgroup. The test for heterogeneity was
not significant (P=0.72, I2=0% ). A fixed mode was
used to analyze the studies. The results showed that pu-
erarin was more effective than Danshen injection. The
difference between the two groups was significant [RR=
1.68, 95%CI (1.32, 2.14), P<0.0001, Figure 6].
Puerarin vs 654-2: there were two studies30,31 in this
subgroup. The test for heterogeneity was not signifi-
cant (P=0.34, I2=0%). A fixed mode was used to ana-
lyze the studies. The result showed that the puerarin
was more effective than 654-2. The difference between
the two group was significant [RR=1.22, 95%CI (1.05,
1.42), P=0.01, Figure 6]
Sensitivity analysis
To indicate the stability of the results of the total effec-
tive rate, we performed sensitivity analyses on the sub-
group "Puerarin+VB vs VB," "Puerarin+mecobalamin vs
mecobalamin," and "Puerarin vs VB." In every sub-
group, we got the results after removal of the most
weighted and the least weighed studies, and changed
the analysis mode. In the "Puerarin + VB vs VB" sub-
group, removing the most weighted Chen et al, 13 the
result was RR=1.45, 95% CI (1.18, 1.77), P=0.0004.
Removing the least weighted Xu,14 was RR=1.58, 95%
CI (1.36, 2.05), P<0.000 01. Changing the fixed mode
to random mode, the result was RR=1.58, 95% CI
(1.29, 1.94), P<0.000 01. For the other two groups
with the same method, the results of the subgroup "Pu-
erarin+mecobalamin vs mecobalamin" were [RR=1.30,
95%CI (1.17, 1.45), P<0.000 01], [RR=1.19, 95%CI
(1.06, 1.34), P=0.003], and [RR=1.25, 95%CI (1.14,
1.37), P<0.0001], respectively. The results of the "Pu-
erarin vs VB" subgroup were [RR=1.96, 95% CI (1.51,
2.54), P<0.000 01], [RR=1.92, 95% CI (1.56, 2.38),
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P<0.000 01], and [RR=1.90, 95%CI (1.55, 2.32), P<
0.000 01]. Compared with previous results, there was
no obvious diversity. Therefore, the degree of study
sensitivity was not high.
Nerve conduction velocity
The Meta-analysis showed that the improvement of
MNCV and SNCV were more efficient than the con-
trol group (Table 2).
Hemorheology index
The examination of changes in hemorheology included
the following indicators: HbA1c, Fb, and ηp. Sustained
high blood sugar can contribute to non-enzymatic gly-
cation of a variety of proteins, which may play a role in
the pathogenesis of chronic complications of diabetes.
HbA1cThere were two studies13,29 that mentioned HbA1c.
The results of "Puerarin vs Danshen" injection were
significantly different [MD=﹣2.10, 95% CI (﹣2.86,
﹣1.34), P<0.000 01], which means that puerarin was
more effective than Danshen injection. However, the
results of "Puerarin + VB vs VB" were not significantly
different for HbA1c. More details are shown in Table
3.
Fibrinogen
There were five studies18,23,27,28,31 that mentioned Fb.
The results of "Puerarin vs VB and puerarin+mecobala-
min vs mecobalamin" were significantly different. The
results of "Puerarin vs vasodilator" were significantly
different [MD=﹣0.31, 95%CI (﹣0.43, ﹣0.19), P<
0.000 01], which means that puerarin is more effective
than vasodilator medication in reducing Fb. More de-
tails are shown in Table 3.
Figure 5 Meta-analysis for comparison of total effective rate between puerarin+ mecobalamin and mecobalamin
Figure 4 Meta-analysis for comparison of effective rate between puerarin-west medicine and west medicine
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ηp
There are seven studies18,21,23,27,28,30,31 that studied ηp. All
results were significantly different, which means that
puerarin is more effective than conventional therapy in
reducing ηp. More details are shown in Table 3.
Safety
In the 22 included studies, three had no ADRs. One
study14 reported five ADRs in the puerarin group in-
cluding three participants with facial flushing and pal-
pitation during the infusion, and two patients with
pain at the infusion point that faded away after admin-
istration. Another study29 reported one patient with pal-
pitations and nausea caused by rapid infusion. The
symptoms disappeared after infusion was slowed
down. No serious ADRs occurred. None of the other
studies mentioned ADRs.
DISCUSSION
After analysis of the studies on puerarin injection, we
can make a conclusion that puerarin is effective and rel-
atively safe in the treatment of DPN. Puerarin was able
Figure 6 Meta-analysis for comparison of total effective rate between puerarin and west medicine
Index
MNCV
SNCV
Peroneal nerve
Median nerve
Peroneal nerve
Median nerve
Group
Puerarin vs vasodilator
Puerarin+Vit B and/or Vit B derivative vs Vit B
and/or Vit B derivative
Puerarin vs vasodilator
Puerarin+Vit B and/or Vit B derivative vs Vit B
and/or Vit B derivative
Puerarin vs vasodilator
Puerarin+Vit B and/or Vit B derivative vs Vit B
and/or Vit B derivative
Puerarin vs vasodilator
Puerarin+Vit B and/or Vit B derivative vs Vit B
and/or Vit B derivative
Number of researches
427-30
812,13,16-18,20-22
128
613,16-18, 21,22
327-29
517,18,20-22
128
613,16-18,21,22
MD (95%CI), P
4.55 (3.03, 6.07)
P<0.000 01
4.96 (3.30,6.63)
P<0.000 01
4.10 (0.66, 7.54)
P=0.02
4.95 (2.98, 6.92)
P<0.000 01
3.61 (2.73, 4.49)
P<0.000 01
4.35 (2.12, 6.57)
P=0.0001
3.20 (0.88, 5.52)
P=0.007
3.27 (2.06, 4.47)
P<0.000 01
Table 2 Sensory nerve conduction velocity and motor nerve conduction velocity
Notes: MNCV: motor nerve conduction velocity; SNCV: sensory nerve conduction velocity.
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to improve total effective rate, correct the NCV index,
and reduce plasma viscosity, fibrinogen, and glycosylat-
ed hemoglobin index. The results of the two previous
systematic reviews of puerarin for the treatment of
DPN also supported the conclusion of the Meta-anal-
ysis.32,33
In TCM theory, DPN is caused by Qi-Ying asthenia
syndrome, context stasis, and loss of tendon support.
Currently, studies show that DPN is the result of mul-
tiple factors: sorbitol, inositol metabolic abnormalities,
microvascular disorders, and non-enzymatic protein
glycosylation.34
Puerarin is an isoflavone extracted from dried Gegen
(Radix Puerariae Lobatae). Some pharmacological ex-
periments show that puerarin can inhibit platelet aggre-
gation, improve PGI2 content, inhibit protein glycosyl-
ation, expand blood vessels, improve microcirculation,
increase blood flow around nerves, and improve
NCV.35,36 Another experiment showed that puerarin
was able to significantly reduce HbA1c levels, which
may promote the repair of nerve tissue.37 Further study
found that puerarin as an aldehyde glucoamylase inhib-
itor, could reduce the content of sorbitol in tissue, and
correct NCV that is decreased by diabetes.38 Based on
these pathological and pharmacological studies and our
findings, puerarin may benefit patients with DPN.
Puerarin injection has been widely used clinically, but
the number of ADRs is increasing. In this Meta-analy-
sis, there were six ADRs in the experimental group,
while there were no ADRs in the control group. One
of the reasons for ADRs might be the purity of puera-
rin. The main components of the extraction of Gegen
(Radix Puerariae Lobatae) are flavonoid glycosides,
which include puerarin, daidzein, daidzin, and other
active ingredients. Mixture of daidzein, daidzin, or oth-
er active ingredients with puerarin may contribute to
ADRs. In addition, the occurrence of ADRs is related
to drug infusion rate, dose, and concentration. There-
fore, puerarin used in clinic should be only as directed
by the drug instructions from manufacturer.39 The inci-
dence of ADRs was not high in the Meta-analysis, and
no serious ADRs occurred. Therefore, puerarin injec-
tion used for the treatment of DPN is relatively safe.
The quality of the articles included was not high, and
there were no large-scale RCTs. Only 18 articles said
that they were "random," and none described specific
random allocation methods. Only one article men-
tioned blinding. This systematic review included only
published studies in databases, and lacked articles from
relevant gray literature, which may cause a selection bi-
as. Only five articles reported ADRs/ADEs from puera-
rin. Therefore, more studies should be done to verify
its safety.
Puerarin injection had a significant effect on DPN by
improving total effective rate, correcting NCV that
was decreased by diabetes, and reducing plasma viscosi-
ty, fibrinogen, and glycosylated hemoglobin index. Pu-
erarin was also relatively safe. However, since the arti-
cles enrolled in the study were not of high quality,
more studies should be conducted to consolidate our
findings.
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